Overview Dividends

(KVUE) Kenvue - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US49177J1025

Pain Relief, Allergy Relief, Skincare, Haircare, Oral Care

EPS (Earnings per Share)

EPS Growth (3y CAGR): -40.11%
EPS Trend (3y Corr): -52.3%

Last SUE: -0.36σ
Qual. Beats: 0

Revenue

Revenue Growth (3y CAGR): 0.00%
Revenue Trend (3y Corr): -26.5%

Last SUE: -0.75σ
Qual. Beats: 0

Risk via 10d forecast
Volatility	28.9%
Value at Risk 5%th	42.4%
Relative Tail Risk	-10.97%

Reward TTM
Sharpe Ratio	-0.86
Alpha	-33.10

Character TTM
Hurst Exponent	0.404
Beta	0.232
Beta Downside	0.311

Drawdowns 3y
Max DD	44.08%
Mean DD	19.30%
Median DD	18.12%

Description: KVUE Kenvue September 29, 2025

Kenvue Inc. (NYSE: KVUE) is a global consumer-health company headquartered in Summit, New Jersey, operating across North America, Europe, the Middle East, Africa, Asia-Pacific and Latin America. The firm was spun out of Johnson & Johnson in 2022 and now trades as a standalone public company.

The business is organized into three product-centric segments:

Self-Care: Over-the-counter (OTC) medicines and wellness items such as cough, cold, allergy, pain, digestive health, smoking-cessation and eye-care products. Core brands include Tylenol, Motrin, Benadryl, Nicorette, Zarbee’s, ORS™, Rhinocort, Calpol and Zyrtec.
Skin Health & Beauty: Personal-care and cosmetics ranging from facial and body moisturizers to hair and sun-care. Flagship names are Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine and OGX.
Essential Health: Oral-care, infant-care, women’s health, wound-care and related categories, anchored by Listerine, Johnson’s, Band-Aid, Stayfree, o.b., Carefree and Desitin.

In its most recent fiscal year (FY 2023), Kenvue reported net sales of roughly $15.9 billion, with the Self-Care segment contributing about 55 % of total revenue and delivering an adjusted EBITDA margin near 19 %. The Skin Health & Beauty segment grew at a 5-6 % compound annual growth rate (CAGR) over the past three years, driven by premium-price positioning and expanding e-commerce penetration.

Key macro-drivers for Kenvue include: (1) steady demand for OTC therapeutics, which the IQVIA OTC market size is projected to exceed $45 billion globally by 2027; (2) inflation-sensitive pricing dynamics, as higher input costs compress margins unless offset by brand-strength pricing power; and (3) shifts in consumer health behavior post-pandemic, with a measurable uptick in self-care spending that outpaces overall retail growth (≈3 % annual excess). These factors collectively shape the firm’s earnings outlook and valuation multiples relative to the broader Personal Care Products sub-industry.

For a deeper quantitative comparison of KVUE’s valuation metrics against peers, you may find ValueRay’s analytical tools useful.

KVUE Stock Overview

Market Cap in USD	31,166m
Sub-Industry	Personal Care Products
IPO / Inception	2023-05-04
Return 12m vs S&P 500	-36.0%
Analyst Rating	3.42 of 5

KVUE Dividends

Metric	Value
Dividend Yield	5.11%
Yield on Cost 5y	3.39%
Yield CAGR 5y	102.50%
Payout Consistency	100.0%
Payout Ratio	92.8%

KVUE Growth Ratios

Metric	Value
CAGR 3y	-13.93%
CAGR/Max DD Calmar Ratio	-0.32
CAGR/Mean DD Pain Ratio	-0.72
Current Volume	46899.6k
Average Volume	43689.2k

Piotroski VR‑10 (Strict, 0-10) 5.5

Net Income (1.43b TTM) > 0 and > 6% of Revenue (6% = 900.4m TTM)

FCFTA 0.06 (>2.0%) and ΔFCFTA 0.81pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue -0.83% (prev -0.03%; Δ -0.79pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.08 (>3.0%) and CFO 2.14b > Net Income 1.43b (YES >=105%, WARN >=100%)

Net Debt (7.97b) to EBITDA (2.94b) ratio: 2.71 <= 3.0 (WARN <= 3.5)

Current Ratio 0.98 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (1.92b) change vs 12m ago -0.05% (target <= -2.0% for YES)

Gross Margin 58.14% (prev 57.78%; Δ 0.36pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 55.40% (prev 57.42%; Δ -2.01pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 5.22 (EBITDA TTM 2.94b / Interest Expense TTM 455.0m) >= 6 (WARN >= 3)

Altman Z'' 0.21

(A) -0.00 = (Total Current Assets 6.03b - Total Current Liabilities 6.16b) / Total Assets 27.25b

(B) -0.00 = Retained Earnings (Balance) -136.0m / Total Assets 27.25b

(D) -0.32 = Book Value of Equity -5.25b / Total Liabilities 16.61b

Total Rating: 0.21 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 57.72

1. Piotroski 5.50pt

2. FCF Yield 4.19%

3. FCF Margin 10.92%

4. Debt/Equity 0.86

5. Debt/Ebitda 2.71

6. ROIC - WACC (= 4.01)%

7. RoE 13.95%

8. Rev. Trend -26.50%

9. EPS Trend -52.31%

What is the price of KVUE shares?

As of November 22, 2025, the stock is trading at USD 16.64 with a total of 46,899,633 shares traded.
Over the past week, the price has changed by -0.12%, over one month by +12.85%, over three months by -21.41% and over the past year by -28.07%.

Is KVUE a buy, sell or hold?

Kenvue has received a consensus analysts rating of 3.42. Therefor, it is recommend to hold KVUE.

Strong Buy: 3
Buy: 2
Hold: 14
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the KVUE price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	19.3	16.2%
Analysts Target Price	19.3	16.2%
ValueRay Target Price	17.3	3.7%

KVUE Fundamental Data Overview November 19, 2025

Market Cap USD = 31.17b (31.17b USD * 1.0 USD.USD)
P/E Trailing = 21.6533
P/E Forward = 14.771
P/S = 2.0769
P/B = 2.9258
P/EG = 0.8294
Beta = 0.658
Revenue TTM = 15.01b USD
EBIT TTM = 2.37b USD
EBITDA TTM = 2.94b USD
Long Term Debt = 7.06b USD (from longTermDebt, last quarter)
Short Term Debt = 1.95b USD (from shortTermDebt, last quarter)
Debt = 9.11b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.97b USD (from netDebt column, last quarter)
Enterprise Value = 39.14b USD (31.17b + Debt 9.11b - CCE 1.14b)
Interest Coverage Ratio = 5.22 (Ebit TTM 2.37b / Interest Expense TTM 455.0m)
FCF Yield = 4.19% (FCF TTM 1.64b / Enterprise Value 39.14b)
FCF Margin = 10.92% (FCF TTM 1.64b / Revenue TTM 15.01b)
Net Margin = 9.55% (Net Income TTM 1.43b / Revenue TTM 15.01b)
Gross Margin = 58.14% ((Revenue TTM 15.01b - Cost of Revenue TTM 6.28b) / Revenue TTM)
Gross Margin QoQ = 59.14% (prev 58.90%)
Tobins Q-Ratio = 1.44 (Enterprise Value 39.14b / Total Assets 27.25b)
Interest Expense / Debt = 1.02% (Interest Expense 93.0m / Debt 9.11b)
Taxrate = 24.33% (128.0m / 526.0m)
NOPAT = 1.80b (EBIT 2.37b * (1 - 24.33%))
Current Ratio = 0.98 (Total Current Assets 6.03b / Total Current Liabilities 6.16b)
Debt / Equity = 0.86 (Debt 9.11b / totalStockholderEquity, last quarter 10.63b)
Debt / EBITDA = 2.71 (Net Debt 7.97b / EBITDA 2.94b)
Debt / FCF = 4.86 (Net Debt 7.97b / FCF TTM 1.64b)
Total Stockholder Equity = 10.27b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.26% (Net Income 1.43b / Total Assets 27.25b)
RoE = 13.95% (Net Income TTM 1.43b / Total Stockholder Equity 10.27b)
RoCE = 13.69% (EBIT 2.37b / Capital Employed (Equity 10.27b + L.T.Debt 7.06b))
RoIC = 9.48% (NOPAT 1.80b / Invested Capital 18.95b)
WACC = 5.47% (E(31.17b)/V(40.27b) * Re(6.84%) + D(9.11b)/V(40.27b) * Rd(1.02%) * (1-Tc(0.24)))
Discount Rate = 6.84% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 33.33 | Cagr: 0.21%
[DCF Debug] Terminal Value 75.41% ; FCFE base≈1.54b ; Y1≈1.29b ; Y5≈962.1m
Fair Price DCF = 9.22 (DCF Value 17.67b / Shares Outstanding 1.92b; 5y FCF grow -19.65% → 3.0% )
EPS Correlation: -52.31 | EPS CAGR: -40.11% | SUE: -0.36 | # QB: 0
Revenue Correlation: -26.50 | Revenue CAGR: 0.0% | SUE: -0.75 | # QB: 0

Additional Sources for KVUE Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle